A detailed history of Strs Ohio transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Strs Ohio holds 201,400 shares of PBYI stock, worth $602,186. This represents 0.0% of its overall portfolio holdings.

Number of Shares
201,400
Previous 159,300 26.43%
Holding current value
$602,186
Previous $519,000 1.16%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$2.25 - $4.03 $94,725 - $169,663
42,100 Added 26.43%
201,400 $513,000
Q2 2024

Aug 05, 2024

BUY
$2.92 - $5.83 $465,156 - $928,719
159,300 New
159,300 $519,000
Q2 2022

Jul 25, 2022

SELL
$1.64 - $3.3 $388,680 - $782,100
-237,000 Closed
0 $0
Q4 2021

Jan 24, 2022

BUY
$2.85 - $6.58 $371,640 - $858,032
130,400 Added 122.33%
237,000 $720,000
Q3 2021

Oct 22, 2021

BUY
$6.63 - $9.39 $186,303 - $263,859
28,100 Added 35.8%
106,600 $747,000
Q2 2021

Jul 26, 2021

BUY
$8.98 - $11.6 $138,292 - $178,640
15,400 Added 24.41%
78,500 $720,000
Q4 2020

Jan 25, 2021

BUY
$7.78 - $12.13 $262,186 - $408,781
33,700 Added 114.63%
63,100 $647,000
Q2 2020

Jul 23, 2020

BUY
$7.01 - $13.24 $40,658 - $76,792
5,800 Added 24.58%
29,400 $306,000
Q4 2019

Jan 24, 2020

BUY
$6.5 - $10.73 $26,650 - $43,993
4,100 Added 21.03%
23,600 $206,000
Q3 2019

Oct 21, 2019

BUY
$8.75 - $12.85 $170,625 - $250,575
19,500 New
19,500 $209,000
Q2 2018

Aug 06, 2018

SELL
$48.3 - $68.25 $806,610 - $1.14 Million
-16,700 Closed
0 $0
Q1 2018

Apr 20, 2018

BUY
$59.7 - $99.25 $149,250 - $248,125
2,500 Added 17.61%
16,700 $1.14 Million
Q4 2017

Jan 23, 2018

BUY
$93.85 - $132.45 $1.08 Million - $1.52 Million
11,500 Added 425.93%
14,200 $1.4 Million
Q3 2017

Oct 23, 2017

BUY
$72.0 - $119.75 $194,400 - $323,325
2,700
2,700 $323,000

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $136M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Strs Ohio Portfolio

Follow Strs Ohio and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.